Global Crohns Disease Market Size By Type (Surgery, Drug Therapy), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Crohn’s Disease Market was valued at USD 12.9 billion in 2023 and is projected to reach USD 21.7 billion by 2031, growing at a CAGR of 6.7% during the forecast period of 2023–2031. The increasing incidence of inflammatory bowel diseases (IBD), coupled with a rise in awareness regarding gastrointestinal health, is significantly contributing to market growth. Advancements in biologics, the growing elderly population, and a rise in patient access to healthcare facilities globally are also key factors fueling the demand for Crohn’s disease treatment.

Drivers:

1. Rising Prevalence of Crohn’s Disease:

The growing number of diagnosed Crohn’s disease cases, especially in developed regions like North America and Europe, is a primary growth driver. Changes in dietary patterns, increased antibiotic usage, and urban lifestyles are believed to contribute to disease incidence.

2. Advancements in Biologic Therapies:

Biologics, particularly TNF inhibitors and integrin receptor antagonists, have revolutionized Crohn’s disease management. The ongoing development of next-generation biologics and biosimilars is expected to enhance treatment outcomes and market penetration.

3. Growing Awareness and Diagnostic Capabilities:

Enhanced diagnostic techniques such as colonoscopy, capsule endoscopy, and biomarkers have improved early diagnosis rates. Increased public awareness and educational campaigns have also contributed to more patients seeking treatment.

Restraints:

1. High Cost of Biologic Drugs:

Despite their efficacy, biologic treatments come with high price tags, making them less accessible, especially in low- and middle-income regions. Limited insurance coverage in some markets further adds to patient burden.

2. Side Effects and Non-Responsiveness:

Not all patients respond favorably to current drug therapies. Biologics can have significant side effects and some patients may develop resistance over time, limiting their long-term effectiveness.

Opportunity:

1. Emerging Markets and Increased Healthcare Access:

Rapid improvements in healthcare infrastructure across Asia-Pacific, Latin America, and the Middle East are opening new opportunities. Rising awareness, improving diagnostics, and government healthcare initiatives in these regions are boosting market potential.

2. Pipeline of Novel Treatments:

Several innovative therapies, including small molecule drugs (e.g., JAK inhibitors), microbiome-based treatments, and personalized medicine approaches, are currently under clinical trials. If approved, these could significantly alter the treatment landscape.

Market by System Type Insights:

By drug class, biologics dominated the market in 2023 due to their superior efficacy in managing moderate to severe Crohn’s cases. TNF inhibitors such as infliximab and adalimumab remain widely used, while newer agents targeting different pathways (e.g., IL-12/23, integrins) are gaining traction. The small molecules segment, particularly JAK inhibitors, is poised to grow rapidly due to their oral administration and promising clinical results.

Market by End-use Insights:

Hospitals held the largest share of the market in 2023, driven by their ability to administer complex biologic therapies and manage acute complications. Specialty clinics are gaining momentum due to a growing preference for outpatient care and chronic disease management services, especially in urban areas with higher Crohn’s prevalence.

Market by Regional Insights:

North America led the global Crohn’s disease market in 2023, holding over 40% of the revenue share. This dominance is attributed to advanced healthcare infrastructure, high disease awareness, and the early adoption of innovative therapies. Europe followed closely, with strong growth seen in Germany, the UK, and France. Asia-Pacific is expected to register the fastest CAGR, driven by rising disease incidence, government investment in healthcare, and expanding access to biologic drugs.

Competitive Scenario:

Key players in the Crohn’s Disease Market include AbbVie Inc., Johnson & Johnson (Janssen), Pfizer Inc., Takeda Pharmaceutical Company, Bristol-Myers Squibb, UCB S.A., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. These companies are investing heavily in R&D, clinical trials, and strategic partnerships to enhance their therapeutic portfolios.

Key developments:

In 2023, Takeda’s Entyvio SC formulation received regulatory approvals in multiple markets, enabling easier administration outside hospital settings.

AbbVie launched Skyrizi, a novel IL-23 inhibitor, approved for Crohn’s disease in 2022, targeting patients unresponsive to TNF inhibitors.

Pfizer expanded its IBD research pipeline in 2024 by acquiring Arena Pharmaceuticals, gaining access to promising candidates like etrasimod.

Scope of Work – Global Crohn’s Disease Market

Report Metric Details

Market Size (2023) USD 12.9 Billion

Projected Market Size (2031) USD 21.7 Billion

CAGR (2023–2031) 6.7%

Market Segments By Drug Class (Biologics, Small Molecules), By End-use (Hospitals, Specialty Clinics)

Growth Drivers Rising incidence of Crohn’s disease, biologic therapy innovation, improved diagnostics

Opportunities Emerging market expansion, pipeline drug approvals, personalized medicine

Key Market Developments:

2023: Takeda launched the subcutaneous version of Entyvio in Europe and North America, expanding patient self-administration options.

2024: Pfizer’s acquisition of Arena Pharmaceuticals brought etrasimod into late-stage development for moderate-to-severe Crohn’s disease.

2025: UCB S.A. received FDA breakthrough designation for its investigational monoclonal antibody bimekizumab targeting IL-17A/F.

FAQs:

1. What is the current market size of the Global Crohn’s Disease Market?

The Global Crohn’s Disease Market was valued at USD 12.9 billion in 2023.

2. What is the major growth driver of the Global Crohn’s Disease Market?

Key growth drivers include the rising prevalence of Crohn’s disease, innovation in biologics, and improved diagnostic technologies.

3. Which is the largest region during the forecast period in the Global Crohn’s Disease Market?

North America is projected to remain the largest regional market during the forecast period.

4. Which segment accounted for the largest market share in Global Crohn’s Disease Market?

Biologics held the largest market share by drug class in 2023.

5. Who are the key market players in the Global Crohn’s Disease Market?

AbbVie, Johnson & Johnson, Pfizer, Takeda, Bristol-Myers Squibb, UCB, Eli Lilly, and Roche are leading players in the market.

Let me know if you'd like this as a downloadable Word document too!